Acamprosate

Generic Name: Acamprosate

Brand Names: Campral

Drug Type: Small Molecule

Chemical Formula: C_₅H_₁₁NO_₄S

CAS Number: 77337-76-9

Unique Ingredient Identifier: N4K14YGM3J

Background: Alcohol use disorder is responsible for a large worldwide burden of morbidity, premature mortality, and economic consequences resulting from accidents, violence, incarceration, decreased productivity, and increased healthcare spending.

Acamprosate, also known by the brand name Campral, is a drug used for the maintenance of alcohol abstinence. It is a structural analogue of the neurotransmitter γ-aminobutyric acid (GABA). Acamprosate is the first medication specifically formulated for the maintenance of alcohol abstinence in ethanol-dependent patients after alcohol detoxification, unlike naltrexone and disulfiram. It was first approved by the FDA in 2004 and initially marketed by Forest Laboratories.

Indication: Acamprosate is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. It is also indicated for the maintenance of alcohol abstinence in patients who have undergone alcohol detoxification. This drug should be used with a psychosocial support program providing adequate support.

Associated Conditions: Alcohol Abstinence, Alcohol Dependency

Clinical Trials

A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia

Phase 2

Withdrawn

Conditions: Drug-induced Tardive Dyskinesia

Interventions: Drug: Placebo
Drug: SNC-102

First Posted Date: 2014-02-17

Last Posted Date: 2021-04-13

Lead Sponsor: Synchroneuron Inc.

Registration Number: NCT02064010

Locations: 🇺🇸
UCLA - Greater Los Angeles, Los Angeles, California, United States

Study of Acamprosate in Fragile x Syndrome

Phase 1

Completed

Conditions: Fragile X Syndrome

Interventions: Drug: Placebo
Drug: acamprosate

First Posted Date: 2013-07-30

Last Posted Date: 2021-02-03

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Target Recruit Count: 46

Registration Number: NCT01911455

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

Study of Acamprosate in Autism

Phase 1

Completed

Conditions: Autistic Disorder

Interventions: Drug: Placebo
Drug: Acamprosate

First Posted Date: 2013-03-18

Last Posted Date: 2021-02-03

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Target Recruit Count: 36

Registration Number: NCT01813318

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Acamprosate in Youth With Fragile X Syndrome

Phase 2

Completed

Conditions: Fragile X Syndrome
Autism Spectrum Disorders

Interventions: Drug: Acamprosate

First Posted Date: 2011-02-23

Last Posted Date: 2019-07-30

Lead Sponsor: Indiana University

Target Recruit Count: 14

Registration Number: NCT01300923

Locations: 🇺🇸
Riley Child and Adolescent Psychiatry Clinic - Riley Hospital for Children, Indianapolis, Indiana, United States

Alcohol Detoxification in Primary Care Treatment (ADEPT)

Phase 4

Completed

Conditions: Alcoholism

First Posted Date: 2009-03-04

Last Posted Date: 2011-01-19

Lead Sponsor: University of Bristol

Target Recruit Count: 36

Registration Number: NCT00855699

Locations: 🇬🇧
University of Bristol, Bristol PCT., Bristol, United Kingdom

Biomarker Study of Acamprosate in Schizophrenia

Phase 4

Completed

Conditions: Schizoaffective Disorder
Schizophrenia

Interventions: Drug: Acamprosate

First Posted Date: 2008-06-02

Last Posted Date: 2019-09-25

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 36

Registration Number: NCT00688324

Locations: 🇺🇸
VA Maryland Health Care System, Baltimore, Maryland, United States
🇺🇸
Keypoint Community Mental Health Centers- Dundalk, Baltimore, Maryland, United States
🇺🇸
Maryland Psychiatric Research Center, Baltimore, Maryland, United States

and more 1 locations